Aclarion, Inc., a healthcare technology company specializing in Magnetic Resonance Spectroscopy (MRS) for the U.S. low back and neck pain market, has filed an amendment to its Form S-3 registration statement with the Securities and Exchange Commission (SEC) on September 19, 2024. The amendment includes details on the company's plans to offer up to $50,000,000 in securities, which may consist of common stock, preferred stock, warrants, subscription rights, debt securities, or units. The securities may be offered from time to time and in one or more series, with the specific terms to be detailed in future prospectus supplements. Aclarion's common stock is quoted on the Nasdaq Capital Market under the symbol 'ACON.' The company has faced compliance issues with Nasdaq...Show More

Aclarion, Inc., a healthcare technology company specializing in Magnetic Resonance Spectroscopy (MRS) for the U.S. low back and neck pain market, has filed an amendment to its Form S-3 registration statement with the Securities and Exchange Commission (SEC) on September 19, 2024. The amendment includes details on the company's plans to offer up to $50,000,000 in securities, which may consist of common stock, preferred stock, warrants, subscription rights, debt securities, or units. The securities may be offered from time to time and in one or more series, with the specific terms to be detailed in future prospectus supplements. Aclarion's common stock is quoted on the Nasdaq Capital Market under the symbol 'ACON.' The company has faced compliance issues with Nasdaq's minimum bid price and stockholders' equity requirements, leading to deficiency letters and an appeal hearing scheduled for October 10, 2024. Aclarion intends to take measures to regain compliance and remain listed on Nasdaq. The registration statement also includes provisions for indemnification of directors and officers, anti-takeover measures, and choice of forum clauses for legal proceedings.